Loneliness as deadly as obesity and smoking pack a day, top health expert warns
Elvis Presley sang it in Heartbreak Hotel and now a top voice in American health says the classic song's chorus has become an alarming reality: Americans are feeling so lonely, they could die.
Vivek Murthy, the former U.S. Surgeon General, is warning that the negative health impacts of chronic loneliness are comparable to some of the nation's biggest killers.
'The overall mortality increase that can be related to social disconnection is comparable to the mortality impact of smoking and obesity,' he told NBC's 'Meet the Press' on Sunday.
'That's how powerful and how important loneliness is.'
He cautioned that loneliness and isolation can raise people's risk for dangerous health conditions
Murthy astonishingly said he found that chronic loneliness is equivalent to smoking 15 cigarettes a day.
'Well, it turns out that our connection with one another, this is not just a nice thing to have, it's biologically an imperative for us,' he said. 'It's something we need for survival, just like we need food and water.'
Raising awareness about the loneliness and isolation epidemic was a large part of his work during the Biden administration, releasing an advisory to call attention to the issue in 2023. The guidance included a six-pronged plan of action, including to enact pro-connection policies, reform digital environments, conduct more related research, and cultivate a culture of connection.
Murthy said then that the consequences of poor social connection with others include a 29 percent increased risk of heart disease, a 32 percent increased risk of stroke, a 50 percent increased risk of developing dementia for older adults, and a 60 percent increased risk of premature death. It is also connected to an increased risk of type 2 diabetes.
Those were only some of the physical repercussions. In addition, the risk of depression among people who report feeling lonely is more than twice that of those who rarely or never feel lonely. Loneliness and social isolation in childhood also increase the risk of depression and anxiety.
In the U.S., about one in three adults report feeling lonely and around one in four report not having social and emotional support, according to the Centers for Disease Control and Prevention.
Certain people and groups are more at-risk, including low-income adults, young adults, older adults, adults living alone, immigrants, people with a mental or physical challenge, people who are victims of violence or abuse, people facing the loss of a love one or unemployment, and people in the LGBTQIA+ community.
Murthy said that kids struggle the most.
'We tend to think, 'Oh. Kids are on social media. That's great because they're connected to one another.' But, no, we have to recognize there's a difference between the connections you have online and the connections you have in person,' Murthy said.
As more relationships have shifted online, more kids are struggling with an 'intense' culture of comparison, are trying to be people they're not, and don't have as many in-person friendships as we need.
'One student [who] I talked to at a college, as I was traveling the country, he said to me ... 'How are we supposed to connect with one another when it's no longer the culture for people to talk to each other?'' Murthy recalled. 'And, I saw that on college campuses,' he said.
A national survey from Harvard University previously found that 73 percent of those surveyed selected technology as contributing to loneliness in the country.
'Parents do have good reason to be worried right now,' Murthy added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
29 minutes ago
- The Independent
Weight loss pill shows promise in new trial
A new weight loss medication, which can be offered by injection or tablet, can help patients lose a significant amount weight, studies suggest. An early study have found that people who received higher doses of amycretin as a weekly jab lost 24.3% of their body weight after 36 weeks of treatment. And initial trials assessing a tablet form of the drug also showed promising results, with patients taking daily tablets losing an average of 13.1% of their body weight after 12 weeks. Weight loss jabs have been hailed as transformative by NHS leaders. But injections come with additional work for over-stretched health services so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out that jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3% after 36 weeks of treatment. It also showed signs in improving blood sugar levels. Side effects included nausea and vomiting and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1% of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7%, with a third of participants losing 25% or more of their body weight after 72 weeks.
Times
2 hours ago
- Times
My brother died at 33 — what I wish I'd known
I remember seeing the troubling spark of recognition in the psychologist's eyes when I told her that my late brother, Charlie, had schizophrenia. We were sitting in her office going through a never-ending pile of forms as part of my seven-year-old son Eddie's autism-assessment process, including my family history. 'Did you know,' she asked, 'that autism used to be known as childhood schizophrenia?' I remember the grating rough texture of the chair I was sitting on prickling against the back of my legs and feeling the inside of my stomach flip. We lost my big brother, Charlie, in 2004 when he was 33 and he hadn't had a particularly happy life. He had been diagnosed with schizophrenia at the age of 18 after a period of psychosis — he had been hearing voices and became convinced that a group of people were out to get him.
The Independent
2 hours ago
- The Independent
Weight loss pill set to rival injections after promising studies
A new daily weight loss pill has shown promising results in initial studies. Researchers say amycretin, which can be offered by injection or tablet, helped patients lose a significant amount of weight in the first trials. Those who received higher doses of amycretin as a weekly jab lost 24.3 per cent of their body weight after 36 weeks of treatment, while patients who took daily tablets lost an average of 13.1 per cent of their body weight after 12 weeks. While weight loss jabs have been hailed as transformative by NHS leaders, injections come with additional work for over-stretched health services, so tablet forms of medication may offer a new hope for the millions of people looking to lose weight. It has been estimated that around 1.5 million Britons are having weight loss jabs, which have been either prescribed through specialist weight loss services or private prescriptions. GPs will be able to dish out jabs from next week. Amycretin, made by Novo Nordisk, helps to control blood sugar and appetite by targeting two specific receptors in the body – GLP-1 and the amylin receptor. An early trial in 125 adults testing weekly injections of amycretin, which has been published in The Lancet, found that those taking the highest dosage (60mg) lost 24.3 per cent after 36 weeks of treatment. It also showed signs of improving blood sugar levels. Side effects included nausea and vomiting, and were mostly mild to moderate and resolved by the end of treatment. 'These phase 1b/2a data support the potential of once-weekly subcutaneous amycretin as a therapeutic for people living with overweight or obesity,' the authors wrote. 'Amycretin appeared safe and tolerable, and there were significant reductions in body weight after 36 weeks of treatment.' The second early trial, published in the same journal, assessed amycretin in tablet form in 144 people over 12 weeks. There were mild to moderate side effects including loss of appetite, nausea and vomiting. Researchers found that people taking the highest dose of 100mg per day, lost 13.1 per cent of their body weight over four months. The authors wrote: 'Amycretin effectively lowered body weight and improved metabolic and glycaemic parameters in people with overweight or obesity. 'Longer studies with more participants are warranted for evaluation of the safety and efficacy of amycretin in individuals living with obesity and type 2 diabetes, and to optimise the dosing regimen.' The studies were also presented at the American Diabetes Association 's Scientific Sessions in Chicago, in the US. It comes as a separate study, which was published at the same meeting, examined the effects of weight loss jab Wegovy at higher doses. Researchers found that giving patients 7.2mg of Wegovy, also known as semaglutide, once a week led to an average weight loss of 20.7 per cent, with a third of participants losing 25 per cent or more of their body weight after 72 weeks.
